Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 16/20 | 0.87 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333973 | 0.92 | CSNK2A1 (0.84) | CSNK2A1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL290812 | 0.90 | CSNK2A1 (0.72) | CSNK2A1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL298156 | 0.89 | CSNK2A1 (0.85) | CSNK2A1KDM4EMEN1USP2LMNA | |
| SCHEMBL291822 | 0.89 | CSNK2A1 (0.77) | CSNK2A1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL291022 | 0.88 | CSNK2A1 (0.76) | CSNK2A1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL19254805 | 0.88 | CSNK2A1 (0.85) | CSNK2A1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL22400125 | 0.86 | CSNK2A1 (0.67) | CSNK2A1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL300829 | 0.86 | CSNK2A1 (0.78) | CSNK2A1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL292369 | 0.85 | CSNK2A1 (0.68) | CSNK2A1KDM4EMEN1USP2LMNA | |
| SCHEMBL19254305 | 0.84 | CSNK2A1 (0.70) | CSNK2A1KDM4EUSP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| US-10765681-B2 | Purine compounds possessing anticancer activity | ACADEMIA SINICA (TW) | 2020-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10765681-B2 | Purine compounds possessing anticancer activity | NTPCR, PNP, NUDT1 | CSNK2A1 2675/4885PIK3CD 1159/4885PIK3CA 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.